Deutsche Bank’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-89,736
| Closed | -$273K | – | 3673 |
|
|
2024
Q4 | $273K | Buy |
89,736
+27,042
| +43% | +$118K | ﹤0.01% | 2961 |
|
|
2024
Q3 | $325K | Buy |
62,694
+25,633
| +69% | +$127K | ﹤0.01% | 2684 |
|
|
2024
Q2 | $95.2K | Sell |
37,061
-8,368
| -18% | -$28.6K | ﹤0.01% | 3128 |
|
|
2024
Q1 | $224K | Buy |
45,429
+1,127
| +3% | +$6.67K | ﹤0.01% | 2769 |
|
|
2023
Q4 | $389K | Sell |
44,302
-740
| -2% | -$6.06K | ﹤0.01% | 2498 |
|
|
2023
Q3 | $517K | Buy |
45,042
+5,200
| +13% | +$100K | ﹤0.01% | 2151 |
|
|
2023
Q2 | $1.01M | Sell |
39,842
-17,676
| -31% | -$551K | ﹤0.01% | 1978 |
|
|
2023
Q1 | $1.85M | Sell |
57,518
-100,801
| -64% | -$3.14M | ﹤0.01% | 1731 |
|
|
2022
Q4 | $2.92M | Buy |
158,319
+125,982
| +390% | +$2.88M | ﹤0.01% | 1449 |
|
|
2022
Q3 | $873K | Sell |
32,337
-8,616
| -21% | -$175K | ﹤0.01% | 2048 |
|
|
2022
Q2 | $566K | Sell |
40,953
-4,809
| -11% | -$74K | ﹤0.01% | 2509 |
|
|
2022
Q1 | $892K | Sell |
45,762
-4,898
| -10% | -$74.3K | ﹤0.01% | 2426 |
|
|
2021
Q4 | $827K | Buy |
50,660
+2,764
| +6% | +$46.1K | ﹤0.01% | 2554 |
|
|
2021
Q3 | $1.33M | Sell |
47,896
-14,791
| -24% | -$422K | ﹤0.01% | 2424 |
|
|
2021
Q2 | $1.86M | Sell |
62,687
-76,766
| -55% | -$2.21M | ﹤0.01% | 2300 |
|
|
2021
Q1 | $3.9M | Buy |
139,453
+89,178
| +177% | +$2.47M | ﹤0.01% | 1696 |
|
|
2020
Q4 | $1.42M | Buy |
50,275
+12,517
| +33% | +$324K | ﹤0.01% | 2185 |
|
|
2020
Q3 | $949K | Sell |
37,758
-96,809
| -72% | -$2.54M | ﹤0.01% | 2229 |
|
|
2020
Q2 | $3.29M | Sell |
134,567
-41,295
| -23% | -$815K | ﹤0.01% | 1520 |
|
|
2020
Q1 | $2.6M | Buy |
175,862
+20,150
| +13% | +$417K | ﹤0.01% | 1563 |
|
|
2019
Q4 | $2.53M | Buy |
155,712
+124,438
| +398% | +$1.93M | ﹤0.01% | 1827 |
|
|
2019
Q3 | $404K | Sell |
31,274
-474,262
| -94% | -$5.8M | ﹤0.01% | 2780 |
|
|
2019
Q2 | $6.55M | Buy |
505,536
+34,789
| +7% | +$438K | ﹤0.01% | 1631 |
|
|
2019
Q1 | $7.42M | Buy |
470,747
+138,927
| +42% | +$2.41M | ﹤0.01% | 1572 |
|
|
2018
Q4 | $6.68M | Buy |
331,820
+98,257
| +42% | +$2.16M | ﹤0.01% | 1556 |
|
|
2018
Q3 | $5.8M | Sell |
233,563
-63,957
| -21% | -$1.74M | ﹤0.01% | 2060 |
|
|
2018
Q2 | $8.17M | Buy |
297,520
+129,781
| +77% | +$3.9M | ﹤0.01% | 1917 |
|
|
2018
Q1 | $5.17M | Buy |
167,739
+39,251
| +31% | +$1.26M | ﹤0.01% | 2188 |
|
|
2017
Q4 | $4.59M | Buy |
128,488
+14,012
| +12% | +$402K | ﹤0.01% | 2096 |
|
|
2017
Q3 | $3.15M | Sell |
114,476
-2,664
| -2% | -$64.6K | ﹤0.01% | 2224 |
|
|
2017
Q2 | $3.09M | Buy |
117,140
+100,595
| +608% | +$2.24M | ﹤0.01% | 2273 |
|
|
2017
Q1 | $343K | Sell |
16,545
-7,412
| -31% | -$152K | ﹤0.01% | 3296 |
|
|
2016
Q4 | $494K | Buy |
23,957
+4,551
| +23% | +$76.2K | ﹤0.01% | 3177 |
|
|
2016
Q3 | $313K | Sell |
19,406
-2,778
| -13% | -$40.3K | ﹤0.01% | 3418 |
|
|
2016
Q2 | $300K | Buy |
22,184
+9,793
| +79% | +$173K | ﹤0.01% | 3550 |
|
|
2016
Q1 | $215K | Buy |
12,391
+6,782
| +121% | +$138K | ﹤0.01% | 3633 |
|
|
2015
Q4 | $190K | Sell |
5,609
-17,707
| -76% | -$614K | ﹤0.01% | 3751 |
|
|
2015
Q3 | $692K | Sell |
23,316
-54,210
| -70% | -$1.65M | ﹤0.01% | 3170 |
|
|
2015
Q2 | $2.48M | Buy |
77,526
+37,759
| +95% | +$971K | ﹤0.01% | 2290 |
|
|
2015
Q1 | $823K | Buy |
39,767
+32,354
| +436% | +$559K | ﹤0.01% | 2988 |
|
|
2014
Q4 | $125K | Sell |
7,413
-3,119
| -30% | -$54.5K | ﹤0.01% | 4573 |
|
|
2014
Q3 | $203K | Sell |
10,532
-3,147
| -23% | -$82K | ﹤0.01% | 4064 |
|
|
2014
Q2 | $464K | Buy |
13,679
+11,929
| +682% | +$374K | ﹤0.01% | 3518 |
|
|
2014
Q1 | $55K | Buy |
+1,750
| New | +$54.7K | ﹤0.01% | 4504 |
|
Other funds holding RVNC
Deutsche Bank's RVNC Position: Q1 2025 in Review
Deutsche Bank sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 89,736 shares — an estimated $273K sold.
Deutsche Bank first reported a position in RVNC in Q1 2014 and held it in 44 quarters. The position peaked at $8.17M in Q2 2018. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Deutsche Bank reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Deutsche Bank sold 89,736 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $273K.
- Deutsche Bank first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 44 quarters.
- Deutsche Bank's Revance Therapeutics, Inc. position peaked at $8.17M in Q2 2018.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Deutsche Bank's 13F filing for Q1 2025, filed 9 May 2025.